AFYREN SAS And Two Other Prominent Penny Stocks

As the European markets navigate a period of profit-taking and political uncertainty, investors are increasingly looking at alternative investment opportunities. Penny stocks, though an older term, continue to capture interest due to their potential for growth at lower price points. By focusing on companies with strong financials and clear growth prospects, investors can uncover hidden gems in the European market that may offer both stability and upside potential.

Click here to see the full list of 275 stocks from our European Penny Stocks screener.

Let’s review some notable picks from our screened stocks.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AFYREN SAS offers alternatives to petroleum-based ingredients using non-food biomass in France, with a market cap of €64.75 million.

Operations: The company generates revenue from its Chemicals segment, amounting to €2.70 million.

Market Cap: €64.75M

AFYREN SAS, with a market cap of €64.75 million, is navigating the challenges typical of penny stocks. The company is pre-revenue, posting sales of €1.2 million for the first half of 2025 and a net loss of €6.92 million. Despite being unprofitable and not expected to achieve profitability in the next three years, AFYREN has more cash than debt and sufficient resources to cover liabilities short term and long term. Revenue growth is forecast at 72.51% per year, but earnings are expected to decline by an average of 3.5% annually over the next three years.

ENXTPA:ALAFY Debt to Equity History and Analysis as at Oct 2025

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Biohit Oyj is a biotechnology company that produces and sells acetaldehyde-binding products, diagnostic tools, and systems for research institutions, healthcare, and industry globally, with a market cap of €45.70 million.

Operations: The company’s revenue primarily comes from its diagnostic kits and equipment segment, generating €14.28 million.

Market Cap: €45.7M

Biohit Oyj, with a market cap of €45.70 million, has shown stable earnings growth and financial health typical of penny stocks. The company reported half-year sales of €7.4 million, consistent with last year, but net income decreased to €0.9 million from €1.2 million. Despite this dip in profitability, Biohit’s short-term assets comfortably cover its liabilities, and it remains debt-free with no shareholder dilution over the past year. Future revenue is projected to grow 15-20% annually through 2028, supported by an expected operating profit margin of at least 10%.

HLSE:BIOBV Financial Position Analysis as at Oct 2025

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Scana ASA is a company that delivers technology and services to the offshore and energy sectors across Norway, Europe, the United States, Asia, and Africa with a market capitalization of NOK720.54 million.

Operations: Scana’s revenue primarily comes from its Energy segment, generating NOK631.8 million, and the Offshore Segment, contributing NOK1.06 billion.

Market Cap: NOK720.54M

Scana ASA, with a market cap of NOK720.54 million, is trading significantly below its estimated fair value and shows potential in the penny stock segment. The company has reduced its debt to equity ratio from 380.8% to 22.2% over five years, indicating improved financial stability despite being unprofitable. Scana’s short-term assets do not cover all liabilities, but it maintains a sufficient cash runway for over three years due to positive free cash flow growth of 23.2% annually. Recent management changes include appointing Baste Tveito as CEO and Morten Riiser as CFO on a permanent basis, signaling strategic shifts within the company.

OB:SCANA Debt to Equity History and Analysis as at Oct 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTPA:ALAFY HLSE:BIOBV and OB:SCANA.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com